Improving outcomes for patients with inflammatory bowel diseases using a biologic care pathway
Improving Patient Outcomes Through the Implementation of a Standardized Biologic Care Pathway in the Treatment and Management of Inflammatory Bowel Disease Pathway in the Treatment and Management of Inflammatory Bowel Disease
This study is testing a new care plan to see if it helps adults with inflammatory bowel diseases, like Crohn's and ulcerative colitis, get better treatment when they start a specific medication.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 182 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT06030882 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the management of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, through the implementation of a standardized biologic care pathway (BCP). By utilizing evidence-based practices, the study will assess how effectively the BCP can be integrated into clinical settings to improve patient health outcomes and streamline healthcare processes. Participants will be adults starting anti-TNF biologic therapy, and the study will evaluate the impact of this approach on treatment consistency and overall patient care.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are beginning anti-TNF biologic therapy or a biosimilar.
Not a fit: Patients with high-grade strictures, perforating complications, active infections, or known malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved health outcomes and more effective management of inflammatory bowel diseases for patients.
How similar studies have performed: Previous studies have shown that implementing clinical care pathways can improve treatment outcomes, suggesting a positive outlook for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Greater than or equal to age 18 * Starting an Anti TNF biologic therapy or Biosimilar Exclusion Criteria: * High-grade, symptomatic fibrostenotic strictures * Perforating complications * Intraabdominal or perianal abscesses * Active infection, * Known malignancy * Any contraindication to biologic therapy
Where this trial is running
Halifax, Nova Scotia
- QEII Health Sciences Centre — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Study coordinator: Jennifer Jones, MD
- Email: jljones@dal.ca
- Phone: 902-473-1499
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.